CDKN2C and neuroblastoma: The analysis of MYCN-amplified versus MYCN-silent neuroblastoma also showed a significant downregulation of CDKN2C in MYCN-amplified samples, suggesting a potential, general oncogenic function for the lowered expression of CDKN2C for MYCN-amplified pediatric cancers.